Abstract Library

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#4431 Systemic treatment in metastatic pheochromocytomas and paragangliomas: Optimal moment for starting and outcomes of a multicentre Spanish cohort

Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs), collectively referred to as PPGLs, are relatively rare endocrine tumours with significant clinical variability and metastatic behaviour. Treatment strategies must be tailored individually due to the heterogeneity in their behaviour.

Conference:

Presenting Author: Del Olmo-García M

Authors: Hernández-Rienda L, Contreras-Saldarriaga J, Hernando Cubero J, García Alvarez A, Prado-Wohlwend S,

Keywords: Pheochromocytoma, paraganglioma, PPGL, metastatic, SSA, Radionuclide, chemotherapy,

#4208 The somatostatin system – A silent messenger in pheochromocytomas and paragangliomas?

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) arising from neural crest-derived chromaffin cells. Due to the abundance of somatostatin receptors (SSTs) on the surface of most NENs, somatostatin analogues (SSAs) have become a cornerstone in their diagnosis and treatment. However, while PPGLs exhibit this feature, their functional responsiveness to SSAs remains limited, with the underlying cause of this resistance being still elusive.

Conference:

Presenting Author:

Authors: García Vioque V, Moreno-Montilla M, Blázquez-Encinas R, Barlier A, Arroba E,

Keywords: pheochromocytomas, paragangliomas, neuroendocrine tumor, somatostatin analogues, treatment resistance,

#4174 Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring

Introduction: Liquid biopsy, notably plasma circulating tumor DNA (ctDNA), is a non-invasive approach to elucidate the tumoral genomic profile from a blood sample. Pheochromocytomas and paragangliomas (PPGL) are often operated, characterized by quiet genomes and usually indolent tumor growth. However, challenges arise with metastatic tumors due to accessibility, catecholamine-related crises and surgery issues. Thus, molecular mechanisms transitioning from indolent to metastatic tumors are largely unexplored.

Conference:

Presenting Author:

Authors: Arenillas Lallana C, Moreno-Cárdenas A, Casteràs A, García-Álvarez A, Hernando J,

Keywords: liquid biopsy, ctDNA, metastasis, pheochromocytoma, paraganglioma, genomic targets,

#4122 Effectiveness and safety of surufatinib in treating pheochromocytomas and paragangliomas

Introduction: Pheochromocytomas and paragangliomas (PPGLs), classified as malignant by WHO in 2017, are partly catecholamine-secreting neuroendocrine tumors (NET). The 5-year overall survival rate of metastases PPGLs (mPPGL) is only between 50% and 60%. Surufatinib, approved for the treatment of NET, with anti-angiogenic and immunomodulatory properties, offers potential as a potential candidate for treating mPPGL.

Conference:

Presenting Author:

Authors: Su T, Zhong X, Song Q, Wang W,

Keywords: Pheochromocytomas and paragangliomas, treatment, Surufatinib,